Nicox/Bausch + Lomb plan US 'blockbuster' glaucoma drug filing
This article was originally published in Scrip
Executive Summary
France's Nicox and Valeant subsidiary Bausch + Lomb have announced plans to file their glaucoma drug Vesneo (latanoprostene bunod) in the US after positive top-line results from a pivotal Phase III trial.